

**Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – March 14, 2012 @ 6:00 p.m.**

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. February 8, 2012 DUR Minutes – Vote
 - B. February 9, 2012 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for November 2011
 - B. Retrospective Drug Utilization Review Response for September 2011
 - C. Medication Coverage Activity for February 2012
 - D. Pharmacy Help Desk Activity for February 2012

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Abstral[®], Lazanda[®], Nucynta[®] ER, and Oxecta[®] – See Appendix C.**
 - A. Oklahoma Bureau of Narcotics and Dangerous Drugs (OBNDD) Speaker, Melton Edminsten, Chief Agent of Diversion
 - B. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

6. **Action Item – Vote to Prior Authorize Xgeva[®] – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize Hydroxyprogesterone Caproate – See Appendix E.**
- A. Product Summary
 - B. SoonerCare Birth Statistics
 - C. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **30 Day Notice to Prior Authorize Kalydeco™ – See Appendix F.**
- A. Cystic Fibrosis Overview
 - B. Product Summary
 - C. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

9. **Action Item – Questions Regarding Annual Review of Ampyra® – See Appendix G.**
- A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

10. **Action Item – Questions Regarding Annual Review of Qutenza® – See Appendix H.**
- A. Current Authorization Criteria
 - B. Trends in Utilization
 - C. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix I.**
12. **Future Business**
- A. Annual Review Requip XL®
 - B. Annual Review Metasolv®
 - C. Fiscal Year 2011 Annual Review
 - D. New Product Reviews
 - E. Medical Product Reviews
13. **Adjournment**